{"url_path":"/sec/nvax/8-k/2026-01-12/item-9-01","section_key":"item-9-01","section_title":"Item 9.01 **","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-01-12","source_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001104659-26-002725-index.html","accession_number":"0001104659-26-002725","cik":"0001000694","ticker":"NVAX","issuer_name":"NOVAVAX INC","edgar_url":"https://www.sec.gov/Archives/edgar/data/1000694/0001104659-26-002725-index.html","primary_entity_key":"0001000694","primary_entity_name":"NOVAVAX INC"},"word_count":81,"has_tables":true,"body_markdown":"**Item 9.01.**\n**Financial Statements and Exhibits.**\n\n \n\n(d) Exhibits.\n\n \n\n**Exhibit No.**\n \n**Description**\n\n[99.1](tm262897d1_ex99-1.htm)\n \n[Investor Presentation of\nNovavax, Inc.](tm262897d1_ex99-1.htm)\n\n104\n \nCover Page Interactive Data File (formatted as Inline XBRL).\n\n \n\n \n\n \n\n \n\n**SIGNATURES**\n\n \n\nPursuant to the requirements\nof the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto\nduly authorized.\n\n \n\n \nNovavax, Inc.\n\n \n \n \n\nDate: January 12, 2026\nBy:\n/s/ Mark Casey\n\n \nName:\nMark Casey\n\n \nTitle:\nExecutive Vice President, Chief Legal Officer and Corporate Secretary"}